Biosimilar Medicines

A list of all biosimilar brands of biological medicines that are subsidised on the Pharmaceutical Benefits Scheme (PBS) in Australia

Biosimilar medicines subsidised on the Pharmaceutical Benefits Scheme

Active ingredient

Reference brand (Sponsor)

Biosimilar brand (Sponsor)

Date Biosimilar listed on the ARTG*

Epoetin lambda

Eprex®
[brand of epoetin alfa] (Janssen-Cilag)

Novicrit® (Sandoz)

27/01/2010

Filgrastim

Neupogen® (Amgen)

Nivestim® (Pfizer)

16/09/2010

Tevagrastim® (Teva Pharma Australia)

29/08/2011

Zarzio® (Sandoz)

07/05/2013

Insulin glargine

Lantus® (Sanofi-Aventis)

Also registered under the brand names Lantus Solostar®, Optisulin®, Optisulin Solostar®, Lambeto®, Edomlus®, Toujeo®, Toujeo Max SoloStar®, Soliqua®

Basaglar® (Eli Lilly Australia)

21/11/2014

Semglee® (Alphapharm) 28/03/2018

Infliximab

Remicade®
(Janssen-Cilag)

Also registered under the brand name Jaximab®

Inflectra® (Pfizer)

Also registered under the brand names Remsima®, Emisima®, Flixceli®

19/08/2015

Renflexis® (Samsung Bioepis AU)

28/11/2016

Follitropin alfa

Gonal F® (Merck Serono Australia)

Also registered under the brand name Pergoveris®

Bemfola® (Gedeon Richter)

Also registered under the brand name Afolia®

27/11/2015

Ovaleap® (Theramex)

10/03/2021

Etanercept

Enbrel® (Pfizer)

Brenzys®(Samsung Bioepis)

22/07/2016

Erelzi® (Sandoz) 30/11/2017

Etera® (Lupin)

Also registered under the brand name Rymti®

01/10/2020

Adalimumab

Humira® (Abbvie)

Amgevita® (Amgen)

09/11/2017

Hadlima® (Samsung Bioepis)

24/01/2018

Hyrimoz® (Sandoz) 01/03/2019
Idacio® (Fresenius Kabi) 17/06/2020
Abrilada® (Pfizer) 22/02/2021

Rituximab

MabThera® (Roche)

Also registered under the brand name Ristova®

Riximyo® (Sandoz)

Also registered under the brand names Rixonfya® , Rixvyda®

30/11/2017

Truxima® (Celltrion),

Also registered under the brand name Ritemvia®, Rituzena®, Tuxella®

16/04/2018

Ruxience® (Pfizer)

03/03/2021

Trastuzumab

Herceptin® (Roche)

Also registered under the brand name Herclon®

Herzuma® (Celltrion)

Also registered under the brand names Simabtra® , Hertuzu®

17/07/2018

Ogivri® (Alphapharm)

11/12/2018

Ontruzant® (Samsung Bioepis) 9/01/2019

Kanjinti® (Amgen)

16/05/2019

Trazimera® (Pfizer)

19/08/2019

Pegfilgrastim

Neulasta® (Amgen)

Also registered under the brand name Tezmota®, Ristempa®

Fulphila® (Alphapharm)

17/08/2018

Neutropeg® (Accord healthcare)

19/08/2019

Ziextenzo® (Sandoz)

06/09/2019

Pelgraz® (Accord Healthcare)

13/12/2019

Bevacizumab

Avastin® (Roche)

Zirabev® (Pfizer)

21/11/2019

Mvasi® (Amgen) 30/06/2020

Enoxaparin

Clexane®(Sanofi-Aventis)

Also registered under the brand names Lovenox, Enoxaparin Winthrop®

Enoxapro® (Apotex)

10/02/2020

Teriparatide

Forteo® (Eli Lilly)

Terrosa® (Gedeon Richter)

01/12/2020

Data correct as 1 May 2021;

* Refer to the Schedule of Pharmaceutical Benefits to identify indications for which the reference brand and biosimilar brand are available for subsidised access (all brands may not be available for all indications).

 The independent expert Pharmaceutical Benefits Advisory Committee (PBAC) recommended Herzuma® and Ogivri® be listed on the PBS as substitutable biosimilars of the Herceptin® reference brand of trastuzumab for the purposes of the Efficient Funding of Chemotherapy Program. The PBAC also recommended Riximyo® and Truxima® be listed as substitutable biosimilars of the MabThera® reference brand of rituximab on this Program. Under section 33(2) of the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011, chemotherapy medicines supplied under the Efficient Funding of Chemotherapy program may be substituted with a different brand of the same chemotherapy medicine. These medicines are not marked with ‘a’-flags in the Schedule of Pharmaceutical Benefits.